July 30, 2018 PR-M07-18-NI-101
“Initiating our Phase I clinical trial for BAT1806, our proposed biosimilar for Actemra®, is an important step for Bio-Thera as we work to develop and commercialize safe and effective biosimilars in China, the EU, the US and the rest of the world,” said Shengfeng Li, CEO, Bio-Thera Solutions. “Biosimilars will provide increased access to important therapeutics to patients around the world.”
Bio-Thera Solutions is developing several additional proposed biosimilars, including a biosimilar version of Avastin®, which is currently being evaluated in a global Phase III clinical trial. Bio-Thera Solutions is also pursuing biosimilar versions of Humira®, Stelara®, Cosentyx® and Simponi®.
1 Actemra® is a registered trademark of Genentech, Inc
2 RoActemra® is a registered trademark of Genentech, Inc
3 Avastin® is a registered trademark of Genentech, Inc
4 Humira® is a registered trademark of Abbvie, Inc
5 Stelara® is a registered trademark of Janssen Biotech, Inc
6 Cosentyx® is a registered trademark of Novartis Pharmaceuticals Corporation
7 Simponi® is a registered trademark of Janssen Biotech, Inc
Contacts
Bio-Thera Solutions, Ltd
Bert E. Thomas IV, +1-410-627-1734
bethomas@bio-thera.com
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.